Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects

Abstract

BACKGROUND/OBJECTIVES: Lactobacillus helveticus LBK-16H-fermented milk products containing tripeptides isoleucine-prolineproline and valine-proline-proline lower blood pressure in hypertensive subjects using office and home blood pressure registration. The present study was aimed to evaluate the effects of two doses of these lactotripeptides on 24-h ambulatory blood pressure and lipidomics profiles in mildly hypertensive subjects. SUBJECTS/METHODS: In a randomized, double-blind, placebo-controlled parallel group study, 89 mildly hypertensive subjects ingested, after a 1-month run-in period, a fermented milk drink with 5 mg per day of lactotripeptides during 3 months, and a milk drink with 50 mg per day of lactotripeptides for the following 3 months, or a placebo milk drink without lactotripeptides. Ambulatory blood pressure (24 h) was recorded at baseline and at the end of the intervention periods. Lipidomics profiles were characterized before and after the 6-month intervention. RESULTS: After the second intervention period (50 mg per day of lactotripeptides), systolic and diastolic 24-h blood pressures decreased significantly in the peptide, but not in the placebo group. However, the treatment effects À 2.6 mm Hg (95% confidence interval (CI): À 5.7 to 0.4) in systolic and À 1.3 mm Hg (95% CI: À 3.4 to 0.8) in diastolic blood pressure did not reach statistic significance. Ingestion of 5 mg per day of lactotripeptides for 3 months did not lower blood pressure. The peptide group was dominated by decrease in multiple phospholipids (PL). CONCLUSIONS: Ingestion of fermented milk with daily dose of 50 mg of lactotripeptides appears to lower elevated blood pressure slightly from the baseline, but not significantly compared with the placebo group and to induce significant decreases in multiple PL.

Health-Promoting Properties of Lactobacillus helveticus

“…The differences between the treatment group and the placebo group were not statistically significant, but the authors concluded that the observed effect may have clinical significance (Jauhiainen et al, 2010, 2012). In addition, Usinger et al (2010) recently reported that LhFM (strain Cardi04) did not inhibit ACE in humans.…”

The role of nutrition and nutraceutical supplements in the treatment of hypertension

“…Milk peptides are beneficial in treating MS [109] . A dose response study showed insignificant reductions in BP [110] . The clinical response is attributed to fermented milk's active peptides which inhibit ACE.…”

“…Bovine casein-derived peptides and whey protein-derived peptides exhibit ACEI activity [102][103][104][105][106][107][108][109][110][111] . These components include B-caseins, B-lg fractions, B2-microglobulin and serum albumin [102][103][104]111] .…”

Lipidomics

“…51 A comparison of patients with low and high HDL-C identified novel cis-expression quantitative trait loci variants in the human leukocyte antigen region associated with low HDL-C. 40 Low HDL-C subjects were found to have elevated TG and diminished lyso-phosphatidylcholine and sphingomyelin. 53 Studies on dietary habits 47,49,55,56 and obesity 57-61 also compared the lipid composition. For example, increased concentrations of TG with long FA chains and ceramides, specifically ceramides (d18:1/24:1), correlated with macrophage infiltration in subcutaneous adipose tissue in subjects with high liver fat content.…”

“…[33][34][35][36][37][38][39][40] A summary of the studies is presented in Table 3. Lipid profiling has shown promising results in diabetes mellitus, [41][42][43][44][45][46][47] CVDs, 35,37,38,48-52 metabolic disorders, 40,53,54 dietary habits, and obesity, 47,49,[55][56][57][58][59][60][61] as well as in determining response to drug therapy. [62][63][64][65] Most studies analyzed either blood or tissue samples (ie, diabetic retinopathy, 46 atherosclerotic plaques, 52 muscle, 47 or adipose tissue).…”